tradingkey.logo

Fate Therapeutics Inc <FATE.OQ> expected to post a loss of 38 cents a share - Earnings Preview

ReutersMay 5, 2025 10:27 PM
  • Fate Therapeutics Inc FATE.OQ FATE.O is expected to show a fall in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • The San Diego California-based company is expected to report a 40.7% decrease in revenue to $1.142 million from $1.93 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Fate Therapeutics Inc is for a loss of 38 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 3.6% in the last three months. ​

  • Wall Street's median 12-month price target for Fate Therapeutics Inc is $5.00​, above​ its last closing price of $1.17. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.43

-0.43

-0.44

Missed

-1.7

Sep. 30 2024

-0.41

-0.43

-0.40

Beat

7.5

Jun. 30 2024

-0.47

-0.48

-0.33

Beat

30.6​

Mar. 31 2024

-0.48

-0.49

-0.47

Beat

3.8

​​Dec. 31 2023

-0.53

-0.52

-0.45

Beat

13.9

Sep. 30 2023

-0.56

-0.57

-0.46

Beat

19.3​

Jun. 30 2023

-0.58

-0.59

-0.54

Beat

8.2

Mar. 31 2023

-0.64

-0.62

-0.19

Beat

69.5

This summary was machine generated May 5 at 22:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI